Market Newsdesk

Summit Therapeutics to Host Q2 2023 Financial Results & Operational Progress Call on August 9, 2023

Conference Call to be Held at 9:00am ET

MENLO PARK, Calif.–(BUSINESS WIRE)–
Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) will host an earnings call to announce its second quarter 2023 financial results and provide an operational update for the Company on Wednesday, August 9, 2023, before the market opens.

Summit will host a live webcast of the earnings conference call at 9:00am ET, which will be accessible through Summit’s website www.smmttx.com. An archived edition of the session will be available on our website.

Summit Therapeutics’ Mission Statement

To build a viable, long-lasting health care organization that assumes full responsibility for designing, developing, trial execution and enrollment, regulatory submission and approval, as well as successful commercialization of patient, physician, caregiver, and societal-friendly medicinal therapy intended to: improve quality of life, increase potential duration of life, and resolve serious medical healthcare needs. To identify and control promising product candidates based on exceptional scientific development and administrational expertise, develop our products in a rapid, cost-efficient manner, and to engage commercialization and/or development partners when appropriate.

We accomplish this by building a team of world class professional scientists and business administrators that apply their experience and knowledge to this mission. Team Summit exists to pose, strategize, and execute a path forward in medicinal therapeutic health care that places Summit in a well-deserved, top market share, leadership position. Team Summit assumes full responsibility for stimulating continuous expansion of knowledge, ability, capability, and well-being for all involved stakeholders and highly-valued shareholders.

About Summit Therapeutics

Summit was founded in 2003 and our shares are listed on the Nasdaq Global Market (symbol ‘SMMT’). We are headquartered in Menlo Park, California, and we have additional offices in Oxford, UK and Cambridge, UK.

For more information, please visit https://www.smmttx.com and follow us on Twitter @summitplc.

About Ivonescimab

Ivonescimab, known as SMT112 in the United States, Canada, Europe, and Japan (Summit’s license territories), and as AK112 in China and Australia, is a novel, potential first-in-class, investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. Ivonescimab was discovered by Akeso Inc. (HKEX Code: 9926.HK, “Akeso”) and is currently engaged in multiple Phase III clinical trials in China. Summit intends to begin multiple Phase III clinical trials in its license territories in 2023. Over 750 patients have been dosed with ivonescimab in clinical studies in China and Australia.

Summit Forward-looking Statements

Any statements in this press release about the Company’s future expectations, plans and prospects, including but not limited to, statements about the clinical and preclinical development of the Company’s product candidates, entry into and actions related to the Company’s partnership with Akeso Inc., the therapeutic potential of the Company’s product candidates, the potential commercialization of the Company’s product candidates, the timing of initiation, completion and availability of data from clinical trials, the potential submission of applications for marketing approvals, the impact of the COVID-19 pandemic on the Company’s operations and clinical trials, potential acquisitions and other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the results of our evaluation of the underlying data in connection with the development and commercialization activities for SMT112, the outcome of discussions with regulatory authorities, including the Food and Drug Administration, the uncertainties inherent in the initiation of future clinical trials, availability and timing of data from ongoing and future clinical trials, the results of such trials, and their success, and global public health crises, including the coronavirus COVID-19 outbreak, that may affect timing and status of our clinical trials and operations, whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials or preclinical studies will be indicative of the results of later clinical trials, whether business development opportunities to expand the Company’s pipeline of drug candidates, including without limitation, through potential acquisitions of, and/or collaborations with, other entities occur, expectations for regulatory approvals, laws and regulations affecting government contracts and funding awards, availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements and other factors discussed in the “Risk Factors” section of filings that the Company makes with the Securities and Exchange Commission. Any change to our ongoing trials could cause delays, affect our future expenses, and add uncertainty to our commercialization efforts, as well as to affect the likelihood of the successful completion of clinical development of SMT112. Accordingly, readers should not place undue reliance on forward-looking statements or information. In addition, any forward-looking statements included in this press release represent the Company’s views only as of the date of this release and should not be relied upon as representing the Company’s views as of any subsequent date. The Company specifically disclaims any obligation to update any forward-looking statements included in this press release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230802984278/en/

Dave Gancarz

SVP, Stakeholder Relations, Business Development, & Corporate Strategy

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Research Genetics Clinical Trials Biotechnology Health Pharmaceutical General Health Science Oncology

MEDIA:

Logo

Surf Air Mobility Announces the Successful Completion of its Acquisition of Southern Airways

Combination Creates the Largest Commuter Airline in the US¹

Following the Close of the Transaction on July 27, 2023, Surf Air Mobility has 69.7 Million Basic Shares Outstanding and 71.6 Million Fully Diluted Shares Outstanding

Surf Air Mobility to Release Financial Results for the Second Quarter 2023 and Provide Full Year 2023 Outlook the week of August 14, 2023

LOS ANGELES–(BUSINESS WIRE)–
Surf Air Mobility Inc. (“Surf Air Mobility” or “SAM”), a regional air mobility platform aiming to sustainably connect the world’s communities, announced today that the transaction between Surf Air Mobility and Southern Airways (“Southern”) closed immediately prior to the listing of Surf Air Mobility on the New York Stock Exchange under the ticker symbol “SRFM” on July 27, 2023. The combination of Surf Air Mobility and Southern will provide the basis for SAM’s anticipated expanded, nationwide regional air mobility platform. Following the close of the transaction on July 27, 2023, Surf Air Mobility has 69,742,981 basic shares outstanding and 71,603,186 fully diluted shares outstanding.

Operational and Financial Highlights, Surf Air and Southern together:

• 450,000 passengers across 48 cities with over 75,000 departures in 2022

• Revenue of $100.6 million for the full year 2022, up 44.6% YoY on a combined basis²
• Operating loss of $(111.7) million for the full year 2022, inclusive of $(33.4) million one-time transaction related expenses and $(38.2) million in stock based compensation

• Cash on hand at July 27, 2023 of $34.7 million, with the ability to draw $100 million in cash advances under the GEM share subscription facility³
• Aircraft financing facility with Jetstream for up to $450 million to finance further expansion

• Fleet order with Textron Aviation Inc. to enable the growth of SAM’s fleet by up to 150 Cessna Grand Caravans

• Exclusive provider to Textron Aviation Inc. of battery electric and hybrid electric powertrain technology for the Cessna Grand Caravan

Surf Air Mobility also announced that it will release its financial results for the second quarter of 2023 and provide outlook for the full year 2023 the week of August 14, 2023.

“Surf Air Mobility is building a regional air mobility platform to sustainably connect the world’s communities. We are thrilled to announce the completion of our transaction, combining Surf Air and Southern into Surf Air Mobility, the largest commuter airline in the US by scheduled departures. We are now well-positioned to build a platform that delivers accessible, affordable, and sustainable regional travel for our customers,” said Stan Little, CEO of Surf Air Mobility. “Our public listing is just the beginning, and we look forward to sharing our journey as we execute on our vision to advance the future of flight.”

Surf Air Mobility intends to accelerate the adoption of green flying by developing, together with its commercial partners, hybrid-electric and fully-electric powertrain technology to upgrade existing fleets. By creating a financing and services infrastructure to enable this transition at an industry-wide level, Surf Air Mobility believes it can bring electrified aircraft to market at scale and substantially reduce the cost and environmental impact of regional flying. Surf Air Mobility believes such cost and environmental impact reductions are achievable by the end of the decade, and that operating as a publicly-traded company and having efficient access to growth capital will enable and accelerate the implementation of its strategic plan.

Sudhin Shahani, co-founder of Surf Air Mobility, continued, “Our end-state is electrification, but our flywheel begins with flying more passengers via network expansion and providing solutions to operators via Aircraft-as-a-Service (ACaaS), which we believe will drive growth in the near- and mid-term. Surf Air Mobility is a scaled – and growing – regional air travel company today, and we believe our path to electrification via supplemental type certification (‘STC’) will position us as a capital efficient, technology-enabled, first mover in the regional air ecosystem.”

ABOUT SURF AIR MOBILITY

Surf Air Mobility is a Los Angeles-based regional air mobility platform expanding the category of regional air travel to reinvent flying through the power of electrification. In an effort to substantially reduce the cost and environmental impact of flying and as the operator of the largest commuter airline in the US, Surf Air Mobility intends to develop powertrain technology with its commercial partners to electrify existing fleets and bring electrified aircraft to market at scale. The management team has deep experience and expertise across aviation, electrification, and consumer technology.

Forward Looking Statements

The information in this press release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, among other things, statements about: Surf Air Mobility’s ability to anticipate the future needs of the air mobility market; future trends in the aviation industry, generally; Surf Air Mobility’s future growth strategy and growth rate and its ability to access its financings, grow its fleet. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “could”, “might”, “plan”, “possible”, “project”, “strive”, “budget”, “forecast”, “expect”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential” or “continue”, or the negatives of these terms or variations of them or similar terminology. These forward-looking statements include, without limitation, statements regarding the satisfaction of required conditions for the listing of the Surf Air Mobility common stock. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: Surf Air Mobility’s future ability to pay contractual obligations and liquidity will depend on operating performance, cash flow and ability to secure adequate financing; Surf Air Mobility’s limited operating history and that Surf Air Mobility has not yet manufactured any hybrid-electric or fully-electric aircraft; the powertrain technology Surf Air Mobility plans to develop does not yet exist; the inability to maintain and strengthen Surf Air’s brand and its reputation as a regional airline; any accidents or incidents involving hybrid-electric or fully-electric aircraft; the inability to accurately forecast demand for products and manage product inventory in an effective and efficient manner; the dependence on third-party partners and suppliers for the components and collaboration in Surf Air Mobility’s development of hybrid-electric and fully-electric powertrains, and any interruptions, disagreements or delays with those partners and suppliers; the inability to execute business objectives and growth strategies successfully or sustain Surf Air Mobility’s growth; the inability of Surf Air Mobility’s customers to pay for Surf Air Mobility’s services; the inability of Surf Air Mobility to obtain additional financing or access the capital markets to fund its ongoing operations on acceptable terms and conditions; the outcome of any legal proceedings that might be instituted against Surf Air, Southern or Surf Air Mobility; changes in applicable laws or regulations, and the impact of the regulatory environment and complexities with compliance related to such environment; and other risks and uncertainties indicated in the prospectus. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements. Although Surf Air Mobility believes that the expectations reflected in the forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. Surf Air Mobility cannot guarantee future results, level of activity, performance or achievements and there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking statements and financial projections. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Surf Air Mobility does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Additional information regarding these and other factors that could affect SAM’s results is included in SAM’s SEC filings, which may be obtained by visiting the SEC’s website at www.sec.gov or the investor relations page on SAM’s website at https://investors.surfair.com under the “Financials—SEC Filings” section. Information contained on, or that is referenced or can be accessed through, our website does not constitute part of this document and inclusions of any website addresses herein are inactive textual references only.

¹Based on the number of scheduled flight departures during 2022

²Financial results are derived from the unaudited pro forma condensed combined statements of operations for the year ended December 31, 2022, which combines the historical audited consolidated statement of operations of Surf Air for the year ended December 31, 2022 and the historical audited consolidated statement of operations of Southern for the year ended December 31, 2022 on a pro forma basis to reflect certain adjustments as described in SAM’s registration statement on Form S-1/S-4 (333-272403)

³Please refer to further details in the company’s registration statement available on the SEC’s website or the Company’s Investor Relations website at https://investors.surfair.com/. This press release does not constitute an offer for the sale of securities.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230801357482/en/

For Press:

[email protected]

For Investors:

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Environment Air Transport Aerospace Manufacturing Sustainability Green Technology Transportation Travel

MEDIA:

Logo

RingCentral Expands Video Offerings With Acquisition of Events and Session Product Lines From Hopin

Completes video portfolio to address enterprise communications needs including meetings, webinars, rooms, and now virtual and hybrid events

BELMONT, Calif.–(BUSINESS WIRE)–RingCentral, Inc. (NYSE: RNG), a leading provider of AI-powered global enterprise cloud communications, video meetings, collaboration, and contact center solutions, today announced the acquisition of select assets from Hopin, a leading provider of online audience engagement technology, including its flagship Events platform and Session product. Hopin Events is an all-in-one event management platform that enables planning and producing virtual and hybrid events. Hopin Session is a highly personalized engagement solution.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230802513699/en/

The acquisition includes technology assets, customer relationships, and engineering, product, and go-to-market talent from Hopin. This acquisition expands RingCentral’s video solutions and strengthens the company’s ability to offer customers more choice, including specialized video use cases around interactive events.

“We see an opportunity to redefine how video communication is experienced. This acquisition is a key next step in our journey to deliver more personalized and engaging video meetings and events for customers,” said Vlad Shmunis, Founder, Chairman, and CEO of RingCentral. “We expect the technology and outstanding talent from Hopin will accelerate our ability to achieve these goals and help us differentiate our entire video portfolio.”

An all-in-one event management platform, Hopin Events is optimized for connecting and engaging attendees and makes planning, producing, and reliving event experiences easy. The platform provides a robust set of features to host virtual or hybrid events of various sizes and formats, including conferences, multi-track sessions, networking, sponsor booths, and robust registration tools. Hopin Session is known for making meetings highly interactive, engaging, and personalized.

“We’ve built a world-leading events platform trusted by both internal and customer-facing teams at large enterprises and SMBs around the world,” said Johnny Boufarhat, Founder and CEO of Hopin. “We are thrilled to see the technology that Hopin has been developing over the years find a new home with RingCentral, a recognized UCaaS and CCaaS leader. We’re excited about RingCentral’s plans to grow and invest in the Events and Session platforms as we continue to pursue our vision of building a Community Suite for creators and influencers.”

The mission of RingCentral is to simplify business communications in any mode, on any device, anywhere, while executing on its vision to deliver intelligent, connected experiences.

RingCentral’s video suite currently includes:

• RingCentral Video – a cloud-based meetings solution that lets customers start, schedule, or join meetings from anywhere, including a web browser, a desktop app, or a mobile app.
• RingCentral Rooms – a cloud-based video conference room solution that brings video collaboration into any space.
• RingCentral Webinar – a solution that allows customers to broadcast a meeting to a large audience of up to 10,000 participants from desktop, browser, or mobile.

With this acquisition, this suite will now be extended to include hosting and management of virtual and hybrid events, all at competitive pricing.

“Amidst the strong desire for a return to live events, budget constraints have hindered pre-pandemic corporate crowd capacities, and organizations continue to grapple with the complexities of hosting quality hybrid meetings, often leaving remote attendees with substandard experiences,” said Melody Brue, VP & Principal Analyst of Modern Work at Moor Insights & Strategy. “RingCentral’s acquisition of the Hopin Events and Hopin Session platforms complements the company’s video product portfolio and helps address challenges in how people gather today. The Hopin Events platform’s maturity and its seasoned team should also position RingCentral to evolve with how people gather virtually in the future.”

The terms of the transaction were not disclosed.

About RingCentral

RingCentral is a leading global provider of cloud-based business communications and collaboration solutions that seamlessly combine phone, messaging, video meetings, and contact center. RingCentral empowers customers with AI-powered conversation intelligence that unlocks insights from their interaction data to accelerate business outcomes. With decades of expertise in reliable and secure cloud communications, RingCentral has earned the trust of millions of customers and thousands of partners worldwide. Visit ringcentral.com to learn more.

© 2023 RingCentral, Inc. All rights reserved. RingCentral and the RingCentral logo are trademarks of RingCentral, Inc.

About Hopin

Hopin is changing the way creators and companies create community online. Millions of people use Hopin’s products, which include StreamYard, Streamable, and Superwave (beta), to create connections, build community, and power their businesses. Hopin is a fully remote company. Learn more at hopin.com.

© 2023 Hopin, Ltd. All rights reserved. Hopin and the Hopin logo are trademarks of Hopin, Ltd.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230802513699/en/

PR Contacts:

Mariana Leventis, RingCentral

650-562-6545

[email protected]

Dave Schools, Hopin

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Apps/Applications Technology VoIP Audio/Video Telecommunications Software Artificial Intelligence

MEDIA:

Logo

Logo

Lantern Pharma to Report Second Quarter 2023 Operating & Financial Results on August 9, 2023 at 4:30 p.m. ET

• Webcast to be held Wednesday, August 9, 4:30 p.m. ET, register here, or at the link below.

DALLAS–(BUSINESS WIRE)–
Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR^® AI and machine learning (“ML”) platform with multiple clinical stage drug programs, today announced that it will host its second quarter 2023 operating and financial results webcast on Wednesday, August 9, 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time.

Management intends to discuss the operating and financial results for the second quarter ended June 30, 2023 and provide guidance on upcoming milestones. Panna Sharma, President and Chief Executive Officer of Lantern Pharma, will lead the call and will be joined by other members of the management team.

To register for the webcast, sign up at the link below:

https://us06web.zoom.us/webinar/register/1016902973506/WN_h4QZ0ZyxR3mZZbNQxa2eMw

A replay of the webcast will be available after the call on the investor relations section of the Company’s website at ir.lanternpharma.com.

About Lantern Pharma:

Lantern Pharma (NASDAQ: LTRN) is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Our proprietary AI and machine learning (ML) platform, RADR^®, leverages over 25 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve billion-dollar, real-world problems in oncology drug development. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, we have accelerated the development of our growing pipeline of therapies including eleven cancer indications and an antibody-drug conjugate (ADC) program. On average, our newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2-3 years and at approximately $1.0-2.0 million per program.

Our lead development programs include two Phase 2 clinical programs and multiple upcoming Phase 1 clinical trials anticipated for 2023. We have also established a wholly-owned subsidiary, Starlight Therapeutics Inc., to focus exclusively on the clinical execution of our promising therapies for CNS and brain cancers, many of which have no effective treatment options. Our AI-driven pipeline of innovative product candidates is estimated to have a combined annual market potential of over $15 billion USD and have the potential to provide life-changing therapies to hundreds of thousands of cancer patients across the world.

Please find more information at:

Website: www.lanternpharma.com

LinkedIn: https://www.linkedin.com/company/lanternpharma/

Twitter/X: @lanternpharma

Lantern Pharma Newsletter – The Spark: Sign-up here

Forward-looking Statements:

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: future events or our future financial performance; the potential advantages of our RADR^® platform in identifying drug candidates and patient populations that are likely to respond to a drug candidate; our strategic plans to advance the development of our drug candidates and antibody drug conjugate (ADC) development program; estimates regarding the development timing for our drug candidates and ADC development program; expectations and estimates regarding clinical trial timing and patient enrollment; our research and development efforts of our internal drug discovery programs and the utilization of our RADR^® platform to streamline the drug development process; our intention to leverage artificial intelligence, machine learning and genomic data to streamline and transform the pace, risk and cost of oncology drug discovery and development and to identify patient populations that would likely respond to a drug candidate; estimates regarding patient populations, potential markets and potential market sizes; sales estimates for our drug candidates and our plans to discover and develop drug candidates and to maximize their commercial potential by advancing such drug candidates ourselves or in collaboration with others. Any statements that are not statements of historical fact (including, without limitation, statements that use words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “model,” “objective,” “aim,” “upcoming,” “should,” “will,” “would,” or the negative of these words or other similar expressions) should be considered forward-looking statements. There are a number of important factors that could cause our actual results to differ materially from those indicated by the forward-looking statements, such as (i) the risk that our research and the research of our collaborators may not be successful, (ii) the risk that none of our product candidates has received FDA marketing approval, and we may not be able to successfully initiate, conduct, or conclude clinical testing for or obtain marketing approval for our product candidates, (iii) the risk that no drug product based on our proprietary RADR^® AI platform has received FDA marketing approval or otherwise been incorporated into a commercial product, and (iv) those other factors set forth in the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission on March 20, 2023. You may access our Annual Report on Form 10-K for the year ended December 31, 2022 under the investor SEC filings tab of our website at www.lanternpharma.com or on the SEC’s website at www.sec.gov. Given these risks and uncertainties, we can give no assurances that our forward-looking statements will prove to be accurate, or that any other results or events projected or contemplated by our forward-looking statements will in fact occur, and we caution investors not to place undue reliance on these statements. All forward-looking statements in this press release represent our judgment as of the date hereof, and, except as otherwise required by law, we disclaim any obligation to update any forward-looking statements to conform the statement to actual results or changes in our expectations.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230802966280/en/

Nicole Leber

Investor Relations Associate

[email protected]

KEYWORDS: Texas United States North America

INDUSTRY KEYWORDS: Biotechnology Health Pharmaceutical Clinical Trials Oncology

MEDIA:

Logo

NICE Named as a Top Provider by Constellation ShortList™ for Contact Center as a Service 2023

NICE’s robust CCaaS portfolio yields a high value for its ability to deliver seamless customer experiences

HOBOKEN, N.J.–(BUSINESS WIRE)–NICE (Nasdaq: NICE) announced that NICE has been recognized by Constellation Research in its latest Constellation ShortList™ for Contact Center as a Service for 2023. The Constellation ShortList™ for Contact Center as a Service names top vendors determined by client inquiries, partner conversations, customer references, vendor selection projects, market share, and internal research.

NICE’s portfolio of Contact Center as a Service (CCaaS) solutions was acknowledged for its flexible delivery models for private, public, and multi-cloud environments; global infrastructure and network footprint for global reach and coverage; ability to integrate and connect to business tools such as CRM, customer data platforms (CDPs), and core customer service operations and help desk solutions; and cross-channel workflow and architected journeys to deliver a comprehensive service that includes always-on self-service content, chatbots, and interactive voice response (IVR) experiences.

NICE’s CCaaS solutions encompass workflow management for process and engagement orchestration, including analytics and reporting on agent and platform performance; a vast library of resource and agent engagement and support tools to boost performance; advanced AI application for voice and sentiment scanning via natural-language processing; and an application of AI and ML models for data analytics, smart routing, next-best agent action, virtual agents (text and voice), and chatbot engagement. NICE enables organizations to continue to meet their customers wherever their journeys begin, from search to omnichannel engagement including voice, messaging, social, SMS, and more.

“As the new era of digital customer experiences takes hold, we enable enterprises worldwide to provide the new digital standard in customer experience,” said Barry Cooper, President, CX Division, NICE. “With the most comprehensive, cloud native suite designed for proactive, digitally fluent, AI-powered experiences, we are helping businesses shift to digital and create new opportunities for better relationships with customers. We are thrilled to be short-listed by Constellation Research for CCaaS.”

Constellation Research evaluated 21 solutions in the Contact Center as a Service market and presents vendors in different categories of the market relevant to early adopters. In addition, products included in this document meet the threshold criteria for this category as determined by Constellation Research. This Constellation ShortList™ of vendors for a market category is compiled through conversations with early adopter clients, independent analysis, and briefings with vendors and partners. Core considerations to be shortlisted for Contact Center as a Service involved AI-powered tools, including smart routing, intelligent workforce planning, agent assist, sentiment analysis, chatbots, Interactive Virtual Agents, data management, and process automation.

About Constellation Research

As an award-winning Silicon Valley-based strategic advisory and futurist analyst firm, Constellation Research serves leaders and organizations navigating the challenges of digital strategy, business-model disruption, and digital transformation. Constellation works closely with solution providers, partners, C-suite executives, board of directors, and its Constellation Executive Network of buy-side leaders to lead the way in research coverage and advise clients on how to achieve valuable business results. Each Constellation ShortList™ is updated at least once per year. Updates may occur after six months if deemed necessary. Constellation clients can work with the analyst and the research team to conduct a more thorough discussion of this ShortList™. Constellation can also provide guidance in vendor selection and contract negotiation.

About NICE

With NICE (Nasdaq: NICE), it’s never been easier for organizations of all sizes around the globe to create extraordinary customer experiences while meeting key business metrics. Featuring the world’s #1 cloud native customer experience platform, CXone, NICE is a worldwide leader in AI-powered self-service and agent-assisted CX software for the contact center – and beyond. Over 25,000 organizations in more than 150 countries, including over 85 of the Fortune 100 companies, partner with NICE to transform – and elevate – every customer interaction. www.nice.com

Trademark Note: NICE and the NICE logo are trademarks or registered trademarks of NICE Ltd. All other marks are trademarks of their respective owners. For a full list of NICE’s marks, please see: www.nice.com/nice-trademarks.

Forward-Looking Statements

This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements, including the statements by Mr. Cooper, are based on the current beliefs, expectations and assumptions of the management of NICE Ltd. (the “Company”). In some cases, such forward-looking statements can be identified by terms such as “believe,” “expect,” “seek,” “may,” “will,” “intend,” “should,” “project,” “anticipate,” “plan,” “estimate,” or similar words. Forward-looking statements are subject to a number of risks and uncertainties that could cause the actual results or performance of the Company to differ materially from those described herein, including but not limited to the impact of changes in economic and business conditions, including as a result of the COVID-19 pandemic; competition; successful execution of the Company’s growth strategy; success and growth of the Company’s cloud Software-as-a-Service business; changes in technology and market requirements; decline in demand for the Company’s products; inability to timely develop and introduce new technologies, products and applications; difficulties or delays in absorbing and integrating acquired operations, products, technologies and personnel; loss of market share; an inability to maintain certain marketing and distribution arrangements; the Company’s dependency on third-party cloud computing platform providers, hosting facilities and service partners;, cyber security attacks or other security breaches against the Company; the effect of newly enacted or modified laws, regulation or standards on the Company and our products and various other factors and uncertainties discussed in our filings with the U.S. Securities and Exchange Commission (the “SEC”). For a more detailed description of the risk factors and uncertainties affecting the company, refer to the Company’s reports filed from time to time with the SEC, including the Company’s Annual Report on Form 20-F. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company undertakes no obligation to update or revise them, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230802636789/en/

Corporate Media Contact

Christopher Irwin-Dudek, +1 201 561 4442, ET, [email protected]

Investors

Marty Cohen, +1 551 256 5354, ET, [email protected]

Omri Arens, +972 3 763 0127, CET, [email protected]

KEYWORDS: United States North America New Jersey

INDUSTRY KEYWORDS: Apps/Applications Mobile/Wireless Technology Security Professional Services Business Software Networks Data Analytics Data Management

MEDIA:

Logo

Ontrak Health Announces Breakthrough Increase in Behavioral Health Diagnoses

Diagnoses Confirmed through Innovative Coach-Provider Collaborations

• Across the company’s book of business 42% of members diagnosed with Substance Use Disorder did not have the diagnosis before enrollment in Ontrak’s WholeHealth+ program

• Other behavioral health conditions with similar post-enrollment results include 27% for Depression, 27% for Bipolar Disorder, 21% for Anxiety, and 20% for Schizophrenia

HENDERSON, Nev.–(BUSINESS WIRE)–
Ontrak, Inc. (NASDAQ: OTRK), a leading AI-powered and telehealth-enabled healthcare company, has completed a study of thousands of members revealing a substantial increase of new behavioral health diagnoses following enrollment in the WholeHealth+ program. The analysis focused on members’ diagnoses 12 months post-enrollment compared to their diagnoses within the 12 months pre-enrollment, ensuring a comprehensive evaluation of the program’s impact on identifying and addressing previously unaddressed behavioral health conditions.

Ontrak’s proprietary AI-imputation algorithm is effectively identifying unaddressed and untreated behavioral health conditions, a key driver of persistent, avoidable healthcare utilization. Ontrak’s dedicated care coaches work closely with complex members, providing personalized support to motivate and enhance health literacy, leading to positive behavior changes and increased utilization of the right-sized care, particularly for crucial behavioral health treatments. Members are supported and motivated to engage in consistent care and treatment where new and untreated diagnosis are being uncovered and addressed.

“Accurate and comprehensive diagnosis data provides valuable insights into population health trends, identifies gaps in care, and guides the development of targeted interventions,” said Dr. Judith Feld, Chief Medical Officer at Ontrak. “Our data-driven approach revolutionizes care management and risk adjustment, ensuring that individuals receive comprehensive and well-coordinated support, ultimately benefiting the members and the health plans that serve them.”

Ontrak’s commitment to updated and new diagnoses mark a significant step forward in healthcare innovation. Embracing this transformative approach, Ontrak empowers health plans to make data-driven decisions, break barriers in mental healthcare, and foster a patient-centered and value-based healthcare system.

About Ontrak, Inc.

Ontrak, Inc. is a leading AI and telehealth-enabled healthcare company, whose mission is to help improve the health and save the lives of as many people as possible. Ontrak identifies, engages, activates, and provides care pathways to treatment for the most vulnerable members of the behavioral health population who would otherwise fall through the cracks of the healthcare system. We engage individuals with anxiety, depression, substance use disorder and chronic disease through personalized care coaching and customized care pathways that help them receive the treatment and advocacy they need, despite the socio-economic, medical and health system barriers that exacerbate the severity of their comorbid illnesses. The company’s integrated intervention platform uses AI, predictive analytics and digital interfaces combined with dozens of care coach engagements to deliver improved member health, better healthcare system utilization, and durable outcomes and savings to healthcare payors.

Learn more at www.ontrakhealth.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230802051336/en/

Jaime Prieto

[email protected]

KEYWORDS: Nevada United States North America

INDUSTRY KEYWORDS: Software Telemedicine/Virtual Medicine Managed Care Health Mental Health Artificial Intelligence Health Technology Technology

MEDIA:

Logo

UnitedHealthcare Community Plan of Ohio Awarded NCQA Health Equity Accreditation

COLUMBUS, Ohio–(BUSINESS WIRE)–
UnitedHealthcare Community Plan of Ohio announced it was awarded Health Equity Accreditation by the National Committee for Quality Assurance (NCQA), a private, nonprofit organization dedicated to improving health care quality.

“Every individual in Ohio deserves access to equitable, high-quality health care,” said Scott Waulters, CEO of UnitedHealthcare Community Plan of Ohio. “This accreditation from NCQA is an honor and a recognition of our commitment to reducing disparities and our dedication to helping people live healthier lives.”

NCQA awards accreditation to organizations that meet or exceed its rigorous requirements. Health Equity Accreditation focuses on the foundation of health equity work, including:

• Building an internal culture that supports the organization’s external health equity work.

• Collecting data that helps the organization create and offer language services and provider networks mindful of individuals’ cultural and linguistic needs.

• Identifying opportunities to reduce health inequities and improve care.

As part of its focus on health equity, NCQA assesses and reports on the quality of managed care plans, managed behavioral health care organizations, preferred provider organizations, new health plans, physician organizations, credentials verification organizations, disease management programs and other health-related programs.

Health Equity Accreditation is a nationally recognized endorsement for purchasers, regulators and consumers to use to distinguish organizations that meet rigorous standards in serving a diverse population.

“Earning Health Equity Accreditation shows that an organization is making a breakthrough in providing excellent health care to diverse populations. I congratulate any organization that achieves this level of distinction,” said NCQA President Margaret E. O’Kane. “Eliminating racial and ethnic disparities in health care is essential to improving the quality of care overall.”

UnitedHealthcare serves more than 2.1 million people in Ohio enrolled in employer-sponsored, individual, Medicare and Medicaid plans, with a network of 211 hospitals, and more than 86,000 physicians and care providers statewide.

For more information about NCQA, visit www.ncqa.org.

About NCQA

NCQA is a private, nonprofit organization dedicated to improving health care quality. NCQA accredits and certifies a wide range of health care organizations. It also recognizes clinicians and practices in key areas of performance. NCQA’s Healthcare Effectiveness Data and Information Set (HEDIS®) is the most widely used performance measurement tool in health care. NCQA’s website (ncqa.org) contains information to help consumers, employers and others make more-informed health care choices. NCQA can be found online at ncqa.org, on Twitter @ncqa, on Facebook at facebook.com/NCQA.org/ and on LinkedIn at linkedin.com/company/ncqa.

About UnitedHealthcare

UnitedHealthcare is dedicated to helping people live healthier lives and making the health system work better for everyone by simplifying the health care experience, meeting consumer health and wellness needs, and sustaining trusted relationships with care providers. In the United States, UnitedHealthcare offers the full spectrum of health benefit programs for individuals, employers, and Medicare and Medicaid beneficiaries, and contracts directly with more than 1.5 million physicians and care professionals, and more than 7,000 hospitals and other care facilities nationwide. The company also provides health benefits and delivers care to people through owned and operated health care facilities in South America. UnitedHealthcare is one of the businesses of UnitedHealth Group (NYSE: UNH), a diversified health care company. For more information, visit UnitedHealthcare at www.uhc.com or follow @UHC on Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230802510808/en/

Theresa Hunter

UnitedHealthcare

(952) 931-4645

[email protected]

KEYWORDS: United States North America Ohio

INDUSTRY KEYWORDS: Professional Services DEI (Diversity, Equity and Inclusion) Health Data Analytics Health Insurance Managed Care General Health

MEDIA:

Posted on August 2, 2023 10:49 am

Rallybio to Present at the 2023 Wedbush PacGrow Healthcare Conference

Rallybio to Present at the 2023 Wedbush PacGrow Healthcare Conference

NEW HAVEN, Conn.–(BUSINESS WIRE)–
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that Steve Uden, M.D., Chief Executive Officer of Rallybio, will participate in a panel discussion, “When You’re One in a Million – Orphan Drug Reimbursement/Regulation,” at the 2023 Wedbush PacGrow Healthcare Conference on August 9, 2023 at 11:00 a.m. ET in New York, NY.

About Rallybio

Rallybio (NASDAQ: RLYB) is a clinical-stage biotechnology company with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. Rallybio has built a broad pipeline of promising product candidates aimed at addressing diseases with unmet medical need in areas of maternal fetal health, complement dysregulation, hematology, and metabolic disorders. The Company has two clinical stage programs: RLYB212, an anti-HPA-1a antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT) and RLYB116, an inhibitor of complement component 5 (C5), with the potential to treat several diseases of complement dysregulation, as well as additional programs in preclinical development.

Rallybio is headquartered in New Haven, Connecticut with an additional facility at the University of Connecticut’s Technology Incubation Program in Farmington, Connecticut. For more information, please visit www.rallybio.com and follow us on LinkedIn and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230726873939/en/

Investor:

Ami Bavishi

Head of Investor Relations and Communications

475-47-RALLY (Ext. 282)

[email protected]

Hannah Deresiewicz

Stern Investor Relations, Inc.

212-362-1200

[email protected]

Media:

Tara DiMilia

908-369-7168

[email protected]

KEYWORDS: United States North America New York Connecticut

INDUSTRY KEYWORDS: Biotechnology Pharmaceutical Health Clinical Trials

MEDIA:

Logo

Stoke Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference

BEDFORD, Mass.–(BUSINESS WIRE)–Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at the Canaccord Genuity 43rd Annual Growth Conference on Wednesday, August 9, 2023, at 4:30 p.m. ET.

A live webcast of the presentation, which will be conducted in fireside chat format, will be available on the Investors & News section of Stoke’s website at https://investor.stoketherapeutics.com/ and can be accessed by following this Link. A replay of the webcast will be available for 30 days following the presentation.

About Stoke Therapeutics

Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines. Using Stoke’s proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Stoke’s first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. Dravet syndrome is one of many diseases caused by a haploinsufficiency, in which a loss of ~50% of normal protein levels leads to disease. Stoke is pursuing the development of STK-002 for the treatment of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. Stoke’s initial focus is haploinsufficiencies and diseases of the central nervous system and the eye, although proof of concept has been demonstrated in other organs, tissues, and systems, supporting its belief in the broad potential for its proprietary approach. Stoke is headquartered in Bedford, Massachusetts with offices in Cambridge, Massachusetts. For more information, visit https://www.stoketherapeutics.com/ or follow Stoke on Twitter at @StokeTx.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230802344569/en/

Stoke Investor Contact:

Eric Rojas

Vice President, Investor Relations

[email protected]

617-312-2754

KEYWORDS: Massachusetts United States North America

INDUSTRY KEYWORDS: Health Biotechnology

MEDIA:

Logo

Toast Launches Catering & Events Platform to Help Restaurants Streamline Event Management, Improve Guest Experience, and Thrive

End-to-end solution is designed to optimize the lengthy event planning and execution process, with features to improve the experience for operators and guests alike

BOSTON–(BUSINESS WIRE)–
Toast (NYSE: TOST), the all-in-one technology platform built for restaurants, today announced the launch of Toast Catering & Events, a new product fully integrated with the Toast point-of-sale (POS) to help restaurants seamlessly manage large catering orders and event planning. Toast Catering & Events supports customizable banquet event orders (BEO), fulfillment tools, and lead management functionality. Toast Catering & Events pairs with Toast Invoicing — a digital invoicing tool that Toast launched in October 2022 — to provide even deeper support for the multiple lines of service many restaurants are running today.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230802787203/en/

According to Toast’s 2022 Voice of the Restaurant Industry survey, restaurants on average are managing seven service models, including catering¹. It continues to be a crucial part of growth for many restaurants — a new Toast survey reports² that nearly two-thirds of restaurant owners and operators say a portion of their sales come from catering.

“As restaurants look to diversify revenue streams, catering and events are top of mind as attractive growth areas,” said Aman Narang, COO and Co-Founder of Toast. “However, an additional service model can mean taking on managing multiple systems that often operate in silos. With Toast Catering & Events, we brought the entire catering and event order management lifecycle — from invoicing to inventory management and accounting — into the Toast platform. By fully integrating the solution into our platform, restaurant owners and operators can not only save time but also better position themselves to build a successful, smoothly operating business.”

Restaurant owners, operators, catering and event managers, and staff can now seamlessly manage the multi-week process of planning and executing events and catering orders. Additionally, the Toast Catering & Events platform allows restaurants to:

• Customize for every occasion: The Catering & Events platform is designed to keep guests satisfied through each step of the planning and execution process. Whether solving for dietary restrictions, designating whether an order is pick-up or delivery, or flagging special pricing, Toast Catering & Events offers the tools and the ability to create digital contracts, quotes, and estimates efficiently. It can support high-volume orders and projects of all kinds.
• Manage everything in one place: Many restaurant owners and operators have managed their catering and event orders manually, on handwritten forms, or through revenue reporting on multiple systems. Through integration with Toast POS, restaurants can see updates and reporting for event orders and all their lines of service on a single platform. The digital experience includes menu integration, customer lists, a calendar view, and integrated sales reporting to create a seamless all-in-one platform experience.
• Easily access transparent pricing and estimates: Guests can quickly access and understand costs and efficiently begin the planning process. They can easily submit catering and events inquiry forms directly online. Payments are simplified as well — guests can use an online invoicing tool to make deposits and payments for an order or event.
• Boost efficiency: With Toast Catering & Events, restaurants can skip the paperwork and automate repetitive tasks with features like digital invoice creation, payment processing, prepping and packing, and even repeat catering orders.

“Toast Catering & Events has integrated our events into our POS seamlessly and even prints the prep tickets at a scheduled time so it is very ‘hands-off,’” said Emily Sands, Private Event Sales Director at Elicit Brewing. “My favorite piece of the system so far is the integration with my calendar. It makes it easy to keep my staff in the loop on what’s going on and what’s coming soon.”

Learn more about Toast Catering & Events.

Forward-looking Statements

This press release contains “forward-looking statements,” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the context of the statement and generally arise when Toast or its management is discussing its beliefs, estimates or expectations. Such statements generally include the words “believes,” “plans,” “intends,” “targets,” “may,” “could,” “should,” “will,” “expects,” “estimates,” “suggests,” “anticipates,” “outlook,” “continues,” or similar expressions. These statements are not historical facts or guarantees of future performance, but represent the beliefs of Toast and its management at the time the statements were made regarding future events which are subject to certain risks, uncertainties and other factors, many of which are outside Toast’s control. Actual results and outcomes may differ materially from what is expressed or forecast in such forward-looking statements. Forward-looking statements include, without limitation, statements regarding the market trends of the restaurant industry and expected results of the launch of Toast Catering & Events.

The forward-looking statements contained in this release are also subject to other risks and uncertainties, including those more fully described in Toast’s filings with the Securities and Exchange Commission (“SEC”), including in the sections entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Toast’s Annual Report on Form 10-K for the year ended December 31, 2022, Toast’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, and Toast’s subsequent SEC filings. Toast can give no assurance that the plans, intentions, expectations or strategies as reflected in or suggested by those forward-looking statements will be attained or achieved. The forward-looking statements in this release are based on information available to Toast as of the date hereof, and Toast disclaims any obligation to update any forward-looking statements, except as required by law. These forward-looking statements should not be relied upon as representing Toast’s views as of any date subsequent to the date of this press release.

About Toast

Toast [NYSE: TOST] is a cloud-based, all-in-one digital technology platform purpose-built for the entire restaurant community. Toast provides a single platform of software as a service, or SaaS; products and financial technology solutions that give restaurants everything they need to run their business across point of sale; operations; digital ordering and delivery; marketing and loyalty; and team management. By serving as the restaurant operating system across dine-in, takeout, and delivery channels, Toast helps restaurants streamline operations, increase revenue, and deliver amazing guest experiences. For more information, visit www.toasttab.com.

_______________________

¹ To help better understand the restaurant industry, Toast conducted a blind survey of 956 restaurant decision-makers from May 13, 2022, to June 28, 2022. Respondents were not made aware that Toast was fielding the study. Panel providers granted incentives to restaurant respondents for participation. Using a standard margin of error calculation, at a confidence interval of 95%, the margin of error on average is +/- 3%.

² To help better understand the restaurant industry, Toast conducted a blind survey of 507 restaurant decision-makers from November 29, 2022 – December 19, 2022. Respondents were not made aware that Toast was fielding the study. Panel providers granted incentives to restaurant respondents for participation. Using a standard margin of error calculation, at a confidence interval of 95%, the margin of error on average is +/- 4.4%.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230802787203/en/

[email protected]

KEYWORDS: Massachusetts United States North America

INDUSTRY KEYWORDS: Banking Software Restaurant/Bar Accounting Other Retail Professional Services Data Management Specialty Technology Small Business Food/Beverage Retail Finance

MEDIA:

Photo

(Photo: Toast)